Intrix

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Intrix

What is Intrix? The Definition and Identity of the Active Ingredient

Property Description
Active ingredient Ceftriaxone Sodium
Form Powder for solution for injection
Pharmacological class Third-generation cephalosporin
Common purpose Elimination of systemic bacterial infections
Origin Semisynthetic

Intrix is a medication whose active core is Ceftriaxone Sodium, a compound classified as a potent, semisynthetic beta-lactam antibiotic. Pharmacologically, it belongs specifically to the third-generation cephalosporin class, positioning it as a broad-spectrum agent used solely to manage serious bacterial infections. This specific identity as a third-generation cephalosporin is essential because it dictates the drug's effectiveness against a wide array of susceptible Gram-negative and Gram-positive microorganisms.


What is the Pharmaceutical Form and General Purpose of Intrix?

Intrix is supplied in the dosage form of a powder for solution for injection or as a premixed product, and its general purpose is the elimination of harmful systemic bacterial infections throughout the body. The drug is intended exclusively for professional administration into the bloodstream via the intravenous (IV) or intramuscular (IM) route. This injectable route is necessary to achieve rapid and high concentrations of the antibiotic in the blood and affected deep tissues, as required for effective systemic action against infection. A typical use scenario involves its application in a hospital setting for severe infections requiring prompt, confirmed action.


How Ceftriaxone Compares to Other Antibiotics

Ceftriaxone functions as a bactericidal agent by disrupting the structure of the bacterial cell wall, and it offers advantages due to its broad spectrum and long half-life. As a third-generation cephalosporin, Ceftriaxone provides superior activity against numerous Gram-negative organisms compared to earlier first- and second-generation compounds. Its key differentiating feature is its extended half-life, which allows the antibiotic to remain active in the body for a longer duration than many related agents. This reinforces its utility in managing a wide scope of susceptible microorganisms.

What side effects are possible with Intrix?

Possible Side Effects and Safety Information

The safety profile of Intrix (Ceftriaxone) describes possible adverse reactions across several body systems, as classified in official regulatory documents. Reactions are categorized by frequency, reflecting observations during clinical trials and post-marketing surveillance.


Frequency-Classified Adverse Reactions

Classification Examples of Officially Listed Reactions
Common (up to 1 in 10) Eosinophilia, Leukopenia, Thrombocytopenia, Diarrhoea (loose stools), Rash, Increased hepatic enzymes (AST/ALT).
Uncommon (up to 1 in 100) Genital fungal infection, Granulocytopenia, Anaemia, Headache, Dizziness, Nausea, Vomiting, Pruritus, Injection site reactions (Phlebitis, pain), Fever, Chills.
Rare/Not Known Pseudomembranous Colitis, Bronchospasm, Anaphylactic shock/reactions, Haemolytic anaemia, Convulsion, Encephalopathy, Stevens-Johnson Syndrome.

Serious Adverse Reactions and Constraints

Official labeling highlights the potential for serious adverse reactions, including life-threatening anaphylactic shock and severe cutaneous events like Toxic Epidermal Necrolysis. Haemolytic anaemia and severe gastrointestinal effects like Clostridium difficile-associated diarrhea are also documented.

Population-Specific Constraints: Intrix is contraindicated in neonates (le 28 days of age) who require simultaneous intravenous calcium-containing solutions due to the risk of life-threatening ceftriaxone-calcium precipitation in the organs. The possibility of cross-hypersensitivity with other beta-lactam agents is also noted. The onset of some severe effects, such as pseudomembranous colitis, may occur during treatment or for up to two months after the therapy is stopped.

Overdose and Emergency Response

An overdose of Intrix (Ceftriaxone Sodium) is officially documented to manifest primarily through gastrointestinal symptoms and severe neurological adverse reactions. The documented gastrointestinal signs include nausea, vomiting, and diarrhoea. Neurological manifestations may involve disturbance of consciousness, such as somnolence, lethargy, or confusion, along with more severe outcomes like seizures and non-convulsive status epilepticus.

Immediate medical attention must be sought if an overdose is suspected or if severe adverse reactions occur. The drug must be discontinued immediately, and adequate emergency measures must be instituted. Regulatory information specifies that treatment is symptomatic and supportive because no specific antidote is known for Ceftriaxone, and drug concentrations cannot be reduced by haemodialysis or peritoneal dialysis.

A critical consideration is the documented risk of drug accumulation in patients with severe renal impairment, which is associated with an increased potential for neurological toxicity. Furthermore, fatal precipitation reactions in neonates have been documented when Ceftriaxone is administered simultaneously with calcium-containing intravenous solutions.

Therapeutic Uses of Intrix

What Intrix Treats: Main Uses and Benefits

Intrix (Ceftriaxone) is an injectable antibiotic commonly used to treat conditions presenting with systemic or localized discomfort caused by severe bacterial infections. The medication supports the management of the illness in situations where patients experience bacterial infection, which may assist with managing the acute illness and supports the avoidance of serious complications.

This medication is applied in addressing acute conditions associated with acute or disruptive episodes such as Septicemia, Bacterial Meningitis, severe Pneumonia, complicated Urinary Tract Infections (UTIs), and Bone and Joint Infections. The primary benefit is that it helps address clusters of intense symptoms related to systemic imbalance, like persistent high fever and chills, contributing to the support of the patient's condition.

The drug is relevant for easing severe infections affecting sensitive internal sites, may assist with reducing the potential impact of long-term tissue damage. It is also applied when appropriate in specific clinical scenarios, such as immediately before certain surgeries as surgical prophylaxis to minimize the risk of post-operative infection, or for treating infections like uncomplicated Gonorrhea. In these contexts, the benefit plays a role in managing the effectiveness of pathogen clearance, contributes to improved comfort during periods of heightened symptoms.


Quick Fact: Relief for Severe Systemic Symptoms

Intrix is commonly used to help with managing the severe symptoms related to systemic imbalance, such as high, persistent fever and chills, that arise when a bacterial infection affects the bloodstream or vital organs.

Regulatory References

  1. NIH MedlinePlus overview of Ceftriaxone

Eligibility and Restrictions for Use

Intrix (Ceftriaxone) eligibility is defined by official regulatory documents, establishing absolute prohibitions for certain populations and conditional use for others.

Contraindications (Must Not Use)

The medicine is strictly contraindicated for patients with a known severe allergy to ceftriaxone, any cephalosporin, or other beta-lactam antibiotics. Use is also prohibited in premature neonates (up to 41 weeks postmenstrual age) and in newborns who are hyperbilirubinemic (jaundiced) or require intravenous calcium solutions. Intrix must never be administered simultaneously with IV calcium solutions in any patient of any age.

Age-Related and Conditional Eligibility

Intrix is established for use in adults and children starting from 15 days of age, provided no contraindications are present. Older adults typically do not require dose adjustments if their liver and kidney functions are normal. Conditional use applies to patients with combined severe renal and hepatic dysfunction, where the daily amount must be closely monitored and often restricted. For pregnancy and lactation, the medicine should only be used if the potential benefit justifies the risk, requiring a decision regarding continuing or discontinuing the medicine or breastfeeding.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Intrix (Ceftriaxone) defines critical administration constraints and systemic interaction patterns.

Interaction Scope Details as per Regulatory Documents
Medicinal Products Calcium-containing intravenous solutions and products, Oral Anticoagulants, Aminoglycosides.
Specific Medicines Warfarin (as an anticoagulant example), Probenecid, Chloramphenicol.
Mechanistic Basis Chemical incompatibility (precipitation risk with calcium); Pharmacodynamic effect (increased bleeding risk with anticoagulants); Antagonism (in vitro with Chloramphenicol).
Timing Rules For patients over 28 days of age, sequential administration of Ceftriaxone and calcium-containing solutions is permitted only after thorough flushing of the IV line.
Population Notes The risk of precipitation with intravenous calcium is strictly heightened in neonates (le 28 days of age).
Restrictions Simultaneous IV administration with calcium-containing solutions is contraindicated in all patients. Calcium-containing diluents must not be used for reconstitution.

Interaction Classifications
Severity Absolute Contraindication (with simultaneous IV calcium) and Clinically Significant Interaction (with Oral Anticoagulants).
Context The precipitation risk is specific to intravenous administration and the presence of calcium.

Official regulatory documents define the product's interaction structure primarily through the absolute contraindication regarding physical incompatibility with intravenous calcium products, which mandates strict separation and dilution restrictions. This is complemented by the pharmacodynamic classification noting the increased bleeding risk when co-administered with oral anticoagulants. This structure establishes mandatory administration rules and recognized systemic effects.

Mechanism of Action

Covalent Inhibition of Bacterial Cell Wall Synthesis

The mechanism of Ceftriaxone involves direct, irreversible inhibition of a key bacterial structure. The drug targets Penicillin-Binding Proteins (PBPs), which are enzymes that catalyze the final peptidoglycan cross-linking step of the bacterial cell wall. By binding covalently to and inactivating these PBPs, the antibiotic functionally halts the construction pathway, inducing a structural defect in the pathogen.

Initiating the Fatal Lytic Cascade

The failure of cell wall construction triggers a subsequent mechanistic cascade within the pathogen. The structural failure and resulting osmotic fragility activate the bacteria’s endogenous enzymes, known as autolysins, which degrade the compromised wall structure. This tandem effect leads to osmotic cell lysis and the structural destruction of the susceptible bacterial cell. This bactericidal effect determines the resulting physiological consequence on the bacterial population.

Mechanistic Constraints and Resistance Factors

The action of this mechanism is constrained by specific microbial factors. The most prevalent limitation is the presence of beta-lactamase enzymes, which can hydrolyze the antibiotic's core structure before it reaches the PBP target. Further limitations involve alterations in PBP structure that reduce the drug's affinity, or changes in outer membrane permeability, which physically restrict access to the target site.

Dosage and Administration Information

How to Use Intrix

Intrix (Ceftriaxone) is administered exclusively via parenteral routes and must be given under the supervision of a trained healthcare professional. The officially approved methods of administration are Intravenous (IV) injection or infusion, and Intramuscular (IM) injection.


Administration and Dosage Principles

Intrix is typically dosed once daily (every 24 hours) for most infections. The standard adult daily dose ranges from 1 to 2 grams (g), with a general maximum daily dose of 4 g for severe cases such as meningitis. For specific, short-course uses like surgical prophylaxis, a single 1 g dose is administered 0.5 to 2 hours before the procedure. Doses for pediatric patients are calculated based on body weight, and doses exceeding 50 mg/kg should be given by slow IV infusion.

Preparation and Handling Requirements

Strict guidelines govern the preparation and co-administration of Intrix. The medication must not be mixed or administered simultaneously with any solutions that contain calcium, including Ringer's solution, due to the risk of precipitate formation. For IV use, the powder is reconstituted with sterile water and further diluted using calcium-free solutions like 0.9% Sodium Chloride. If the IM route is used, the powder must be reconstituted with 1% lidocaine solution; this lidocaine-containing solution must never be administered intravenously.

Treatment Duration

The duration of therapy is determined by the specific condition and the patient’s response. Administration should generally continue for at least 48 to 72 hours after the patient has become fever-free and the clinical evidence of infection has resolved. Dose adjustments are not routinely required for older adults or patients with renal impairment alone, but the dose should not exceed 2 g daily when both severe kidney and liver dysfunction are present.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Initial Phase II and III trials focusing on Compound X evaluated whether joint function and the frequency or intensity of inflammation and pain were affected in adults with chronic inflammatory conditions. Research has explored this compound as a potential therapeutic approach.

Early-Stage Research: Initial Efficacy

  • The trials were based on a study hypothesis focusing on the Janus Kinase (JAK) pathway.
  • The trials included a diverse patient group, with the primary studies lasting 12 to 24 weeks.
  • Study reports noted the frequency of adverse events was low.

Combination Therapy vs. Monotherapy

A key Phase III study examined whether combining Compound X with standard treatments was more beneficial than using Compound X alone. The study compared the combination to monotherapy and reported a difference in the magnitude of reduction of pain and stiffness favoring the combination group.

Study Metric Endpoint Duration Combination Group Finding
Primary Endpoint 24 weeks Change in disease activity score
Secondary Outcome Not uniformly met Examination of the need for other pain medications

Long-Term Safety and Effect

Long-term follow-up studies extending up to two years explored the sustained presence of reported benefits and the safety profile. Studies examined whether the drug affected the long-term prognosis for joint health.

  • Adverse event rates remained consistent over the full study period, though data on withdrawal rates were noted.
  • In a subgroup of patients with severe disease, studies reported a change in symptom scores and mobility metrics.
  • Evidence remains limited regarding the compound’s potential role in preventing irreversible joint damage.

Frequently Asked Questions (FAQ)

Common questions about Intrix (FAQ)


Q: Is Intrix used for conditions other than the main one listed?

A: According to official product information, Intrix is approved to treat a wide spectrum of serious bacterial infections throughout the body. These approved uses include infections of the lower respiratory tract, skin and soft tissue, bones and joints, urinary tract, and intra-abdominal area. It is also indicated for serious conditions such as bacterial septicemia and meningitis.


Q: How is Intrix different from [Similar Drug Name]?

A: Intrix (Ceftriaxone) belongs to the third-generation cephalosporin class of antibiotics. Its key differentiating feature, noted in official documents, is its extended half-life. This long duration of action allows the medicine to maintain effective levels in the body with a single, once-daily dose, unlike many related antibiotics that require more frequent administration.


Q: Are there common but minor side effects of Intrix that aren't listed on the main page?

A: Regulatory documents contain a comprehensive list of known side effects, which are officially classified based on how often they occurred in studies. This full list includes both common and uncommon reactions observed during clinical trials and post-marketing surveillance. The complete classification of effects is contained within the official regulatory documentation.


Q: Can taking Intrix affect my driving ability?

A: Official safety information indicates that the medication may cause dizziness, which is listed as an uncommon side effect. Regulatory warnings note that caution is required due to this potential effect. Regulatory guidance suggests that, due to the potential for dizziness, activities such as driving or operating machinery should be managed with caution.


Q: What are the signs that a side effect from Intrix might be serious?

A: Regulatory documents specifically warn about signs of serious reactions that require immediate attention. These include severe allergic reactions such as swelling of the face, difficulty breathing, or a severe skin rash. Another serious warning relates to severe, persistent diarrhea, which may indicate a serious related bowel condition.


Q: Is Intrix safe for people who have liver disease?

A: The official product information addresses the use of Intrix in patients with impaired organ function. Dose adjustment is not routinely needed for individuals with liver problems, provided their kidney function is normal. However, if both severe kidney and severe liver dysfunction are present together, the dosage needs careful monitoring and adjustment.


Q: Why are people with a history of [Specific Condition] advised against taking Intrix?

A: Official regulatory warnings are based on the risk of specific, known complications. For example, in certain newborns, Intrix is contraindicated because it can displace a substance called bilirubin from albumin. This displacement carries the potential risk of a serious neurological condition called bilirubin encephalopathy in that population.


Q: Is Intrix considered a short-term or a long-term treatment?

A: The duration of treatment is determined by the specific infection and the patient's response. It is not exclusively a short-term therapy. Administration may range from a single dose for preventive measures, such as surgical prophylaxis, up to several weeks for serious, complex infections like meningitis.


Q: Are there specific times of day that Intrix should be taken for best effect?

A: Official regulatory dosing guidelines focus primarily on the interval of administration to maintain effective medicine concentration. Since Intrix has an extended half-life, it is typically given once every 24 hours. The guidance does not generally specify an optimal time of day (such as morning or evening) for administration.


Q: If Intrix is helping, how will I know or feel it?

A: The intended effect of Intrix is to eliminate the harmful bacterial infection. Signs of clinical improvement are typically recognized by the healthcare professional, such as when the patient becomes fever-free. The medicine is continued for a minimum time after this clinical evidence of infection has resolved.


Q: Do I need any special tests or monitoring while taking Intrix?

A: Official documents indicate that monitoring is required, especially during longer courses of therapy or in patients who have pre-existing organ problems. This monitoring involves checking blood parameters, including complete blood counts, as well as liver and kidney function tests at regular intervals.


Q: What is the half-life of Intrix?

A: Clinical pharmacology data states that Intrix has a relatively long elimination half-life in healthy adults, ranging from approximately 5.8 to 8.7 hours. This long half-life is the reason the medicine can be effectively given as a single daily dose.


Q: What should I do if I get a rash while taking Intrix?

A: A mild rash is noted as a common side effect of Intrix. However, regulatory warnings highlight that the development of any severe skin rash, blistering, or signs of swelling in the face or throat are serious symptoms that require professional attention. These symptoms may be signs of a serious, life-threatening allergic reaction.


Q: Does Intrix start working right away, or does it take a few weeks?

A: Intrix is administered via injection to achieve rapid and high concentrations in the bloodstream, where it begins its action to kill the bacteria. Because it targets acute bacterial infections, the patient's clinical symptoms typically begin to resolve within days, not weeks. Treatment is usually continued for a minimum of 48 to 72 hours after the fever has fully disappeared.


Q: Is Intrix known to cause weight gain?

A: According to the official regulatory documentation that lists known side effects, weight gain is not noted as a common, uncommon, or rare adverse reaction associated with Intrix use.


Q: Is it true that Intrix interacts with alcohol?

A: Regulatory information clarifies that Intrix (Ceftriaxone) is not known to cause a specific, severe disulfiram-like reaction when combined with alcohol, which is a known issue with some other antibiotics. The regulatory documents do not provide specific general advice on alcohol consumption.


Q: Are there any foods or drinks I need to avoid while on Intrix?

A: The absolute contraindication for Intrix involves mixing or simultaneous administration with intravenous calcium-containing solutions. Beyond this crucial safety rule, official labeling does not typically include restrictions regarding the consumption of general foods or non-alcoholic drinks.


Q: Does Intrix interact with common over-the-counter pain relievers like ibuprofen?

A: Official documents warn that Intrix carries a risk of increasing the effects of oral anticoagulants, which can increase the risk of bleeding. Co-administration with other non-prescription medicines that also affect blood clotting may require caution and monitoring by a healthcare professional.


Q: Does Intrix have to be tapered off, or can I stop taking it whenever?

A: The medicine is an antibiotic, and regulatory guidance emphasizes the need to complete the full, prescribed duration of the treatment course. The course of treatment must be continued for a minimum period after the clinical signs of infection have resolved. Tapering procedures, which are used for certain other drug types, are not mentioned in the official instructions.


Q: Is Intrix available as a generic medicine?

A: The active core of Intrix, Ceftriaxone Sodium, is a widely used compound. As such, the active ingredient is generally available as a generic medicine supplied by various manufacturers.


Q: Is Intrix addictive or habit-forming?

A: Intrix (Ceftriaxone) is classified as an antibiotic and is not designated as a controlled substance. Official safety and pharmacological information indicates that it is not known to be addictive or habit-forming.


Q: Can Intrix cause changes in mood or anxiety levels?

A: Official safety data does not specifically mention changes in mood or anxiety. However, the medicine has been associated with rare central nervous system adverse effects. These rare effects include symptoms like headache, dizziness, and, in severe cases, changes in personality or concentration.


Q: Can I get Intrix without a prescription in some countries?

A: In major regulatory jurisdictions, Intrix (Ceftriaxone) is classified as a prescription-only medicine. It is an injectable product that must be administered only under the direct supervision of a healthcare professional.


Q: Are there any known issues with taking Intrix with dairy products?

A: The absolute safety contraindication for Intrix is specific to the simultaneous administration of the medicine with intravenous calcium solutions. Official regulatory warnings do not include restrictions regarding the general consumption of dietary products, such as dairy.


Q: Does Intrix show up on drug tests?

A: Intrix (Ceftriaxone) is an antibiotic that is not classified as a controlled substance. Standard drug screening tests are typically designed to detect substances of abuse and not prescription antibiotics like Ceftriaxone.


Q: Is Intrix considered a controlled substance?

A: Intrix (Ceftriaxone) is an antibiotic and is not classified as a controlled substance under major international drug scheduling systems.


Q: Do I need to change my diet while on Intrix?

A: Based on official labeling, there are no general regulatory requirements that mandate a patient must change their overall diet while receiving treatment with Intrix.


Q: Is the 'Black Box Warning' (if applicable) for Intrix something I should worry about?

A: Intrix does not feature a Black Box Warning in the main sections of its regulatory prescribing information. However, official documents do contain prominent warnings and contraindications regarding the fatal risk of precipitate formation when it is administered simultaneously with intravenous calcium solutions, particularly in newborns.

How should Intrix be stored and disposed of?

How to Store and Dispose of Intrix?

The storage and disposal of Intrix (Ceftriaxone Sodium powder for injection) must adhere strictly to official regulatory labeling to ensure product quality and safety.

Storage Conditions

Product Form Temperature and Protection Requirements
Unreconstituted Powder Store at Controlled Room Temperature (20, C to 25, C) and protected from light. The powder must not be frozen.
Reconstituted Solution Has a limited stability period and must be used within specified hours at room temperature or up to several days if stored under refrigeration (2, C to 8, C).

The medication must be kept in its original container and stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Intrix must not be discarded in household waste or released into wastewater systems. Disposal must be conducted through official channels, such as a designated pharmaceutical waste program, in accordance with local environmental regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Intrix found in:

A-Z Index: